MedTrace Logo

Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

NCT07166315 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2025-09-10

No results posted yet for this study

Summary

This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.

Conditions

  • Axial Spondylarthritis (axSpA)
  • Psoriatic Arthritis (PsA)

Interventions

OTHER

observational study

This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.

Sponsors & Collaborators

  • Adelphi Real World

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-07
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07166315 on ClinicalTrials.gov